Synonyms: 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name)
Compound class:
Antibody
Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions [1].
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 [5]. |
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
7920 | epratuzumab |
Synonyms |
90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name) |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 40 |
Other databases | |
DrugBank Ligand | DB04958 |
GtoPdb PubChem SID | 249565768 |
Search PubMed clinical trials | epratuzumab |
Search PubMed titles | epratuzumab |
Search PubMed titles/abstracts | epratuzumab |
Wikipedia | Epratuzumab |